More Startups
This investment carries considerable risks and may lead to a loss of the entire assets invested. Projected returns cannot be guaranteed and may be lower than expected.

Medipee | Overview

Medipee automates and digitalizes urine analysis in homes – conveniently, simply, and hygienically.
Pitch Video


Medipee is a startup in the field of medical technology that is revolutionizing preventive health care and bringing it directly into people’s own homes. The analysis of urine provides a lot of important medical information concerning, for example, its sugar content, whether there is blood in the urine, or nitrite content (a result of bacterial breakdown processes). The device developed by Medipee provides this information in an automatic, hygienic, and easy manner.

Medipee - Key Investment Facts

 

Medipee is developing a system for an automated urine analysis. Urine analysis is an essential building block for health care and contains a lot of medical information.

Analysis of blood, ketone, glucose, pH, cancer, pregnancy and drugs are made possible through urine analyses. People with specific illnesses such as patients with kidney problems or diabetes (type 2) have to carry out tests regularly.

Although most people would like to know if they are “healthy,” very few do regular analyses because these are often unpleasant and time intensive. Medipee offers a simple and automated method to analyze urine, as though occurring on second thought.

 

Medipee - App 

The user attaches Medipee's device on the outside of the toilet. Only a small part of the device is in the toilet bowl itself.

The device connects to one’s smartphone via Bluetooth and is ready to go. Within seconds of the device detecting the flow of urine, the automated measurement occurs.

The device automatically measures the urine values, transmits those values to the smartphone, and disposes of the test strip;t the user does not have to worry about anything. After 30 test procedures, the cartridge can be changed without coming into contact with urine.

Also in the planning is a B2B (business-to-business) variant that can be implemented in doctors’ offices, nursing homes, and hospitals. Business angel Frank Willems, who was involved in the exit of Adhesys Medical among others, supports Medipee in its operative business.

The Companists’ investment will be used to finance the device and app development of the B2C (business-to-consumer) variant and to expedite its market launch in early 2019.

Please note
The acquisition of this asset involves considerable risks and can lead to the complete loss of the assets used. The expected yield is not guaranteed and may turn out to be lower.
Contact Us
If you have any questions about investing on Companisto, please contact our service team:


Toll-free phone number for investors

0800 - 100 267 0 (DE)
0800 - 100 267(AT / CH)

We are available Monday through Friday between 9 a.m. – 7 p.m.

For companies
Apply for financing Investment Model FAQ for Companies
Investor Support
Please register in order to see the complete profile of Medipee.
Already registered?    Log in